339 related articles for article (PubMed ID: 15310997)
41. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
[TBL] [Abstract][Full Text] [Related]
42. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
Gittelman M; Ramsdell J; Young J; McNicholas T
J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
[TBL] [Abstract][Full Text] [Related]
43. Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Brown CT; Nuttall MC
Int J Clin Pract; 2003 Oct; 57(8):705-9. PubMed ID: 14627182
[TBL] [Abstract][Full Text] [Related]
44. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
45. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
[TBL] [Abstract][Full Text] [Related]
46. Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.
Mostaghel EA; Geng L; Holcomb I; Coleman IM; Lucas J; True LD; Nelson PS
Cancer Res; 2010 Feb; 70(4):1286-95. PubMed ID: 20124490
[TBL] [Abstract][Full Text] [Related]
47. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat.
Wright AS; Thomas LN; Douglas RC; Lazier CB; Rittmaster RS
J Clin Invest; 1996 Dec; 98(11):2558-63. PubMed ID: 8958218
[TBL] [Abstract][Full Text] [Related]
48. [Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate].
Boccon-Gibod L; Valton M; Ibrahim H; Boccon-Gibod L; Comenducci A
Prog Urol; 2005 Dec; 15(6):1085-9. PubMed ID: 16429657
[TBL] [Abstract][Full Text] [Related]
49. An overview on 5alpha-reductase inhibitors.
Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
[TBL] [Abstract][Full Text] [Related]
50. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
Hong SK; Min GE; Ha SB; Doo SH; Kang MY; Park HJ; Yoon CY; Jeong SJ; Byun SS; Lee SE
BJU Int; 2010 Apr; 105(7):970-4. PubMed ID: 19793378
[TBL] [Abstract][Full Text] [Related]
51. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
[TBL] [Abstract][Full Text] [Related]
52. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
Ravish IR; Nerli RB; Amarkhed SS
Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459
[TBL] [Abstract][Full Text] [Related]
53. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
54. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
Serfling R; Shulman M; Thompson GL; Xiao Z; Benaim E; Roehrborn CG; Rittmaster R
J Urol; 2007 Jun; 177(6):2352-6. PubMed ID: 17509357
[TBL] [Abstract][Full Text] [Related]
55. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study.
Kravchick S; Cytron S; Mamonov A; Peled R; Linov L
Urology; 2009 Jun; 73(6):1274-8. PubMed ID: 19375786
[TBL] [Abstract][Full Text] [Related]
56. Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.
Schulman C; Pommerville P; Höfner K; Wachs B
BJU Int; 2006 Jan; 97(1):73-9; discussion 79-80. PubMed ID: 16336332
[TBL] [Abstract][Full Text] [Related]
57. Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates.
Busetto GM; Giovannone R; Antonini G; Rossi A; Del Giudice F; Tricarico S; Ragonesi G; Gentile V; De Berardinis E
BJU Int; 2015 Jul; 116(1):117-23. PubMed ID: 25291499
[TBL] [Abstract][Full Text] [Related]
58. Suppressive effects of the antiandrogen agent, chlormadinone acetate and the 5alpha-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats.
Kobayashi H; Gotanda K; Shibata Y; Watanabe J; Nakano Y; Shinbo A; Suzuki K
Arzneimittelforschung; 2011; 61(9):515-20. PubMed ID: 22029228
[TBL] [Abstract][Full Text] [Related]
59. Dutasteride (Avodart) for prevention of prostate cancer.
Med Lett Drugs Ther; 2010 Apr; 52(1336):29. PubMed ID: 20407415
[No Abstract] [Full Text] [Related]
60. Dutasteride significantly improves quality of life measures in patients with enlarged prostate.
O'Leary MP; Roehrborn CG; Black L
Prostate Cancer Prostatic Dis; 2008; 11(2):129-33. PubMed ID: 17592479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
